Myocarditis and Pericarditis After Vaccination for COVID-19

George A Diaz; Guilford T Parsons; Sara K Gering; Audrey R Meier; Ian V Hutchinson; Ari Robicsek

doi:10.1001/jama.2021.13443

Myocarditis and Pericarditis After Vaccination for COVID-19

JAMA. 2021 Sep 28;326(12):1210-1212. doi: 10.1001/jama.2021.13443.

Authors

George A Diaz¹, Guilford T Parsons², Sara K Gering³, Audrey R Meier⁴, Ian V Hutchinson⁵, Ari Robicsek²

Affiliations

¹ Section of Infectious Diseases, Providence Regional Medical Center Everett, Everett, Washington.
² Providence Research Network, Renton, Washington.
³ Medical Intensive Care Unit, Providence Regional Medical Center Everett, Everett, Washington.
⁴ Department of Infection Prevention and Control, Providence Regional Medical Center Everett, Everett, Washington.
⁵ Office of Clinical Research, Providence Health and Services, Southern California Region, Los Angeles.

Abstract

This study investigates the incidence of myocarditis and pericarditis emergency department or inpatient hospital encounters before COVID-19 vaccine availability (January 2019–January 2021) and during a COVID-19 vaccination period (February-May 2021) in a large US health care system.

Publication types

Multicenter Study

MeSH terms

2019-nCoV Vaccine mRNA-1273
Ad26COVS1
Adult
Aged
BNT162 Vaccine
COVID-19 / prevention & control*
COVID-19 Vaccines / administration & dosage
COVID-19 Vaccines / adverse effects*
Confidence Intervals
Female
Hospitalization / statistics & numerical data
Humans
Incidence
Los Angeles / epidemiology
Male
Middle Aged
Montana / epidemiology
Myocarditis / epidemiology
Myocarditis / etiology*
Oregon / epidemiology
Pericarditis / epidemiology
Pericarditis / etiology*
Poisson Distribution
Time Factors
Washington / epidemiology

Substances

Ad26COVS1
COVID-19 Vaccines
2019-nCoV Vaccine mRNA-1273
BNT162 Vaccine